Oncologie and Merck will launch a phase II trial to investigate Merck’s Keytruda (pembrolizumab) and Oncologie’s bavituximab, an antibody that blocks the activity of phosphatidylserine (PS) in advanced gastric or gastroesophageal cancer. International trials like this one — enrolling patients in the United States, the UK, Korea, and Taiwan — are a particular specialty at Yourway.